These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 12171714)

  • 1. Pharmacokinetics of CAMPATH-1H in BMT patients.
    Rebello P; Cwynarski K; Varughese M; Eades A; Apperley JF; Hale G
    Cytotherapy; 2001; 3(4):261-7. PubMed ID: 12171714
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CAMPATH-1 antibodies in stem-cell transplantation.
    Hale G; Cobbold S; Novitzky N; Bunjes D; Willemze R; Prentice HG; Milligan D; MacKinnon S; Waldmann H;
    Cytotherapy; 2001; 3(3):145-64. PubMed ID: 12171722
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact on T-cell depletion and CD34+ cell recovery using humanised CD52 monoclonal antibody (CAMPATH-1H) in BM and PSBC collections; comparison with CAMPATH-1M and CAMPATH-1G.
    Williams RJ; Clarke E; Blair A; Evely R; Hale G; Waldmann H; Brookes S; Pamphilon DH
    Cytotherapy; 2000; 2(1):5-14. PubMed ID: 12042050
    [TBL] [Abstract][Full Text] [Related]  

  • 4. T-cell-depleted allogeneic bone marrow transplantation for acute leukaemia using Campath-1 antibodies and post-transplant administration of donor's peripheral blood lymphocytes for prevention of relapse.
    Naparstek E; Or R; Nagler A; Cividalli G; Engelhard D; Aker M; Gimon Z; Manny N; Sacks T; Tochner Z
    Br J Haematol; 1995 Mar; 89(3):506-15. PubMed ID: 7734348
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The CD52 antigen and development of the CAMPATH antibodies.
    Hale G
    Cytotherapy; 2001; 3(3):137-43. PubMed ID: 12171721
    [No Abstract]   [Full Text] [Related]  

  • 6. Control of graft-versus-host disease and graft rejection by T cell depletion of donor and recipient with Campath-1 antibodies. Results of matched sibling transplants for malignant diseases.
    Hale G; Waldmann H
    Bone Marrow Transplant; 1994 May; 13(5):597-611. PubMed ID: 8054913
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CD52 antibodies for prevention of graft-versus-host disease and graft rejection following transplantation of allogeneic peripheral blood stem cells.
    Hale G; Jacobs P; Wood L; Fibbe WE; Barge R; Novitzky N; Toit C; Abrahams L; Thomas V; Bunjes D; Duncker C; Wiesneth M; Selleslag D; Hidajat M; Starobinski M; Bird P; Waldmann H
    Bone Marrow Transplant; 2000 Jul; 26(1):69-76. PubMed ID: 10918407
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Engraftment of marrow allografts treated with Campath-1 monoclonal antibodies.
    Naparstek E; Delukina M; Or R; Nagler A; Kapelushnik J; Varadi G; Strauss N; Cividalli G; Aker M; Brautbar C; Waldmann H; Hale G; Slavin S
    Exp Hematol; 1999 Jul; 27(7):1210-8. PubMed ID: 10390197
    [TBL] [Abstract][Full Text] [Related]  

  • 9. T-cell depleting antibodies: new hope for induction of allograft tolerance in bone marrow transplantation?
    Simpson D
    BioDrugs; 2003; 17(3):147-54. PubMed ID: 12749751
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improving the outcome of bone marrow transplantation by using CD52 monoclonal antibodies to prevent graft-versus-host disease and graft rejection.
    Hale G; Zhang MJ; Bunjes D; Prentice HG; Spence D; Horowitz MM; Barrett AJ; Waldmann H
    Blood; 1998 Dec; 92(12):4581-90. PubMed ID: 9845524
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Campath-1G causes rapid depletion of circulating host dendritic cells (DCs) before allogeneic transplantation but does not delay donor DC reconstitution.
    Klangsinsirikul P; Carter GI; Byrne JL; Hale G; Russell NH
    Blood; 2002 Apr; 99(7):2586-91. PubMed ID: 11895797
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CAMPATH-1 monoclonal antibodies in bone marrow transplantation.
    Hale G; Waldmann H
    J Hematother; 1994; 3(1):15-31. PubMed ID: 7922004
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effects of Campath 1H upon graft-versus-host disease, infection, relapse, and immune reconstitution in recipients of pediatric unrelated transplants.
    Shah AJ; Kapoor N; Crooks GM; Weinberg KI; Azim HA; Killen R; Kuo L; Rushing T; Kohn DB; Parkman R
    Biol Blood Marrow Transplant; 2007 May; 13(5):584-93. PubMed ID: 17448918
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevention of graft vs. host disease with alemtuzumab 'in the bag' decreases early toxicity of stem cell transplantation and in multiple myeloma is associated with improved long-term outcome.
    Novitzky N; Thomas V; du Toit C
    Cytotherapy; 2008; 10(1):45-53. PubMed ID: 18202974
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alemtuzumab in stem cell transplantation.
    Hale G
    Med Oncol; 2002; 19 Suppl():S33-47. PubMed ID: 12180491
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low-dose alemtuzumab (Campath) in myeloablative allogeneic stem cell transplantation for CD52-positive malignancies: decreased incidence of acute graft-versus-host-disease with unique pharmacokinetics.
    Khouri IF; Albitar M; Saliba RM; Ippoliti C; Ma YC; Keating MJ; Champlin RE
    Bone Marrow Transplant; 2004 Apr; 33(8):833-7. PubMed ID: 14755312
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alemtuzumab (Campath-1H) for treatment of lymphoid malignancies in the age of nonmyeloablative conditioning?
    Hale G; Slavin S; Goldman JM; Mackinnon S; Giralt S; Waldmann H
    Bone Marrow Transplant; 2002 Dec; 30(12):797-804. PubMed ID: 12476271
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alemtuzumab (Campath-1H) in allogeneic stem cell transplantation: where do we go from here?
    Chakrabarti S; Hale G; Waldmann H
    Transplant Proc; 2004 Jun; 36(5):1225-7. PubMed ID: 15251298
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of CAMPATH-1H: assay development and validation.
    Rebello P; Hale G
    J Immunol Methods; 2002 Feb; 260(1-2):285-302. PubMed ID: 11792397
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Infectious complications following T-cell depleted hematopoietic stem-cell transplantation.
    Novitzky N; Rouskova A
    Cytotherapy; 2001; 3(3):165-73. PubMed ID: 12171723
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.